CY1119642T1 - CSF-1R Suspensions for Brain Tumor Therapy - Google Patents

CSF-1R Suspensions for Brain Tumor Therapy

Info

Publication number
CY1119642T1
CY1119642T1 CY20171100426T CY171100426T CY1119642T1 CY 1119642 T1 CY1119642 T1 CY 1119642T1 CY 20171100426 T CY20171100426 T CY 20171100426T CY 171100426 T CY171100426 T CY 171100426T CY 1119642 T1 CY1119642 T1 CY 1119642T1
Authority
CY
Cyprus
Prior art keywords
brain tumor
csf
suspensions
tumor therapy
treatment
Prior art date
Application number
CY20171100426T
Other languages
Greek (el)
Inventor
Dylan DANIEL
Johanna JOYCE
James Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119642T1 publication Critical patent/CY1119642T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση του χημικού τύπου I, όπου το R1 είναι μια αλκύλ πυραζόλη ή μια αλκύλ καρβοξαμίδη, και το R2 είναι ένα υδροξυκυκλοαλκύλ, ή ένα φαρμακευτικώς αποδεκτό άλας αυτών, και συνθέσεις που περιέχουν αυτές τις ενώσεις, για χρήση στην θεραπεία ενός όγκου του εγκεφάλου, συγκεκριμένα του γλοιοβλαστώματος. Η εφεύρεση παρέχει αποτελεσματική θεραπεία ενός όγκου του εγκεφάλου και μπορεί να χρησιμοποιηθεί μέσω χορήγησης από του στόματος μιας ένωσης του χημικού τύπου I όπως περιγράφηκε εκτενώς στο παρόν. Γονιδιακές υπογραφές που σχετίζονται με επιτυχημένη θεραπεία χρησιμοποιώντας αυτές τις μεθόδους επίσης εσωκλείονται.The present invention provides a compound of formula I, wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl, or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use in the treatment of a brain tumor, in particular glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of formula I as described herein extensively. Gene signatures associated with successful treatment using these methods are also enclosed.

CY20171100426T 2011-05-05 2017-04-10 CSF-1R Suspensions for Brain Tumor Therapy CY1119642T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482723P 2011-05-05 2011-05-05
US201261624861P 2012-04-16 2012-04-16
PCT/US2012/036589 WO2012151523A1 (en) 2011-05-05 2012-05-04 Csf-1r inhibitors for treatment of brain tumors

Publications (1)

Publication Number Publication Date
CY1119642T1 true CY1119642T1 (en) 2018-04-04

Family

ID=46062775

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100426T CY1119642T1 (en) 2011-05-05 2017-04-10 CSF-1R Suspensions for Brain Tumor Therapy

Country Status (19)

Country Link
US (3) US20140065141A1 (en)
EP (1) EP2704713B1 (en)
JP (1) JP6046702B2 (en)
KR (1) KR101938431B1 (en)
CN (1) CN103501785B (en)
BR (1) BR112013028095B1 (en)
CA (1) CA2834696C (en)
CY (1) CY1119642T1 (en)
DK (1) DK2704713T3 (en)
EA (1) EA023999B1 (en)
ES (1) ES2622527T3 (en)
HR (1) HRP20170593T1 (en)
HU (1) HUE032754T2 (en)
LT (1) LT2704713T (en)
MX (1) MX347616B (en)
PL (1) PL2704713T3 (en)
PT (1) PT2704713T (en)
SI (1) SI2704713T1 (en)
WO (1) WO2012151523A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
JP6851322B2 (en) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル How to treat neurological disorders
CN108367070B (en) 2015-11-04 2022-10-28 杜克大学 Combination therapy of immunotoxins with checkpoint inhibitors
WO2018069892A1 (en) * 2016-10-14 2018-04-19 Novartis Ag Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
WO2018069893A1 (en) * 2016-10-14 2018-04-19 Novartis Ag Methods for treating ocular disease using inhibitors of csf-1r
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
MX2019014268A (en) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy.
CA3064597A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
JP2022513685A (en) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド Methods for Treatment with Adoptive Cell Therapy
EP3886894B1 (en) 2018-11-30 2024-03-13 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
CN110468210A (en) * 2019-09-12 2019-11-19 暨南大学 CDC45 is as glioblast tumor markers and its as the application of therapy target
AU2020395318A1 (en) 2019-12-06 2022-06-09 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
WO2022057895A1 (en) * 2020-09-21 2022-03-24 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721656B1 (en) 2005-11-01 2007-05-23 주식회사 엘지화학 Organic electronic devices
PL2010496T3 (en) * 2006-04-14 2011-01-31 Astrazeneca Ab 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
SI2010528T1 (en) * 2006-04-19 2018-02-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
CN101432281B (en) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
PE20080074A1 (en) 2006-04-20 2008-02-11 Janssen Pharmaceutica Nv AMIDE DERIVATIVES AS INHIBITING AGENTS OF C-FMS KINASE
CA2685967A1 (en) * 2007-05-21 2008-11-21 Novartis Ag Csf-1r inhibitors, compositions, and methods of use

Also Published As

Publication number Publication date
US10537561B2 (en) 2020-01-21
LT2704713T (en) 2017-04-25
JP2014513136A (en) 2014-05-29
KR101938431B1 (en) 2019-01-14
BR112013028095A2 (en) 2016-12-27
SI2704713T1 (en) 2017-05-31
CN103501785A (en) 2014-01-08
JP6046702B2 (en) 2016-12-21
EA201391629A1 (en) 2016-01-29
HUE032754T2 (en) 2017-10-30
AU2012250574A1 (en) 2013-11-28
CN103501785B (en) 2016-10-26
KR20140029475A (en) 2014-03-10
ES2622527T3 (en) 2017-07-06
MX2013012939A (en) 2014-02-27
WO2012151523A1 (en) 2012-11-08
US20190030013A1 (en) 2019-01-31
AU2012250574B2 (en) 2016-07-07
CA2834696C (en) 2019-07-23
PT2704713T (en) 2017-04-24
PL2704713T3 (en) 2017-08-31
US20150306085A1 (en) 2015-10-29
MX347616B (en) 2017-05-04
BR112013028095B1 (en) 2020-03-03
EA023999B1 (en) 2016-08-31
CA2834696A1 (en) 2012-11-08
US20140065141A1 (en) 2014-03-06
DK2704713T3 (en) 2017-04-24
HRP20170593T1 (en) 2017-07-14
EP2704713A1 (en) 2014-03-12
EP2704713B1 (en) 2017-01-18
AU2012250574A8 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
CY1119642T1 (en) CSF-1R Suspensions for Brain Tumor Therapy
CY1122498T1 (en) SECONDARY DERIVATIVES OF IVACAFTOR
CY1122610T1 (en) ALKOXY PYRAZOLES AS SOLVENT ACTIVATORS OF WANYLATE CYCLES
CY1120334T1 (en) Substituted 3-Halogenoyl Alamine SSAO Suspensions and Their Uses
CY1121320T1 (en) USE OF A KIDNEY HORMOND MODIFIING FACTOR
CY1121763T1 (en) DIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
CY1122601T1 (en) GSK3 INHIBITORS AND METHODS OF USING THEREOF
CY1120104T1 (en) Suspensions of SYK
CY1124113T1 (en) COMPOSITIONS AND METHODS FOR THE THERAPEUTIC TREATMENT OF CNS DISORDERS
CY1121231T1 (en) TETRAHYDROMIDAZE PRODUCT [1,5-D] [1,4] OXAZEPINE
CY1119939T1 (en) 2,3-Dihydro-Benzo [1,4] Oxazine Derivative and Related Compounds such as Phosphoinositin-3-Kinase (R3K) Inhibitors for Therapeutic Therapy
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CY1117105T1 (en) PYRIDAZINONIN COMPOUNDS AND USE AS DAAO SUSPENSIONS
CY1118379T1 (en) DISEASES OF USVITIS C
CY1123616T1 (en) 7-BENZYL-4-(4-(TRIFLUOROMETHYL)BENZYL)-1,2,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(4H)- ONI, AND ITS SALTS AND THEIR USE IN THERAPY
UY34451A (en) URACILO DERIVATIVES AS INHIBITORS OF THE AXL AND C-MET KINASE
EA201291409A1 (en) DERIVATIVES OF INDOLYSINE, METHOD OF THEIR PRODUCTION AND THEIR THERAPEUTIC APPLICATION
EA201391568A1 (en) NEW IMIDAZOL DERIVATIVES SUITABLE FOR THE TREATMENT OF ARTHRITIS
CY1118662T1 (en) NEW BICYCLE PYRIDINONS
EA201291414A1 (en) IMIDAZOPIRIDINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THERAPEUTIC USE
EA201790599A1 (en) COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS
EA201391029A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
CY1117122T1 (en) PYRAZOLOSPIRACETONE PRODUCTS FOR USE AS ACETYL-COA CARBOXYLATION INHIBITORS
CY1120378T1 (en) Substituted Derivatized Butane Phosphonic Acid Binding Derivatives as Water Inhibitors
CY1118371T1 (en) IAP SUSPENSIONS